Jan. 4 Quick Takes: Delay for FDA sinks Celgene CVR; plus NASDAQ updates for Clene, Gracell; a Provention PDUFA and more

Strike one, Celgene CVR is out
Bristol Myers Squibb Co. (NYSE:BMY) said a potential $6.8 billion contingent value right issued in the pharma’s $74 billion acquisition of Celgene Corp. in 2019 has terminated automatically after lisocabtagene maraleucel failed to gain approval by Dec. 31. FDA has not been able to complete its review of the therapy, which had a Nov. 16 PDUFA date, because the agency delayed its inspection of a Texas facility where the cell therapy is being manufactured due to pandemic-related travel restrictions. Liso-cel’s approval was the second of three milestones that would have satisfied the CVR’s terms.

SPAC deal lands Clene on NASDAQ
Clene Nanomedicine Inc. (NASDAQ:CLNN) has reached the public markets via a merger with SPAC Tottenham Acquisition Ltd. The neurodegenerative disease company raised $31.9 million in the deal...